Bio-Path Releases Early Cut Data From Mid-Stage Prexigebersen Trial In Acute Myeloid Leukemia
Portfolio Pulse from Vandana Singh
Bio-Path Holdings Inc reported interim data from Stage 2 of its Phase 2 study of prexigebersen for acute myeloid leukemia (AML). The drug, in combination with decitabine and venetoclax, showed compelling efficacy results in two reporting cohorts. The complete remission rate was significantly higher than that for patients treated with the frontline combination of decitabine and venetoclax. Despite the positive results, BPTH shares are down 7.57%.
August 04, 2023 | 10:15 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Despite positive trial results for Bio-Path's prexigebersen, the company's shares are down 7.57%.
The positive trial results would typically be expected to boost the company's stock. However, the stock has fallen, suggesting that other factors may be influencing the price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100